These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33097612)

  • 41. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
    Catenacci DVT; Kang YK; Park H; Uronis HE; Lee KW; Ng MCH; Enzinger PC; Park SH; Gold PJ; Lacy J; Hochster HS; Oh SC; Kim YH; Marrone KA; Kelly RJ; Juergens RA; Kim JG; Bendell JC; Alcindor T; Sym SJ; Song EK; Chee CE; Chao Y; Kim S; Lockhart AC; Knutson KL; Yen J; Franovic A; Nordstrom JL; Li D; Wigginton J; Davidson-Moncada JK; Rosales MK; Bang YJ;
    Lancet Oncol; 2020 Aug; 21(8):1066-1076. PubMed ID: 32653053
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
    de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
    Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
    Shen L; Guo J; Zhang Q; Pan H; Yuan Y; Bai Y; Liu T; Zhou Q; Zhao J; Shu Y; Huang X; Wang S; Wang J; Zhou A; Ye D; Sun T; Gao Y; Yang S; Wang Z; Li J; Wu YL
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561638
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
    Patnaik A; LoRusso PM; Messersmith WA; Papadopoulos KP; Gore L; Beeram M; Ramakrishnan V; Kim AH; Beyer JC; Mason Shih L; Darbonne WC; Xin Y; Yu R; Xiang H; Brachmann RK; Weekes CD
    Cancer Chemother Pharmacol; 2014 May; 73(5):951-60. PubMed ID: 24633809
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.
    Segal NH; He AR; Doi T; Levy R; Bhatia S; Pishvaian MJ; Cesari R; Chen Y; Davis CB; Huang B; Thall AD; Gopal AK
    Clin Cancer Res; 2018 Apr; 24(8):1816-1823. PubMed ID: 29549159
    [No Abstract]   [Full Text] [Related]  

  • 46. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.
    Bilusic M; Heery CR; Collins JM; Donahue RN; Palena C; Madan RA; Karzai F; Marté JL; Strauss J; Gatti-Mays ME; Schlom J; Gulley JL
    J Immunother Cancer; 2019 Sep; 7(1):240. PubMed ID: 31488216
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.
    Xu J; Zhang Y; Jia R; Yue C; Chang L; Liu R; Zhang G; Zhao C; Zhang Y; Chen C; Wang Y; Yi X; Hu Z; Zou J; Wang Q
    Clin Cancer Res; 2019 Jan; 25(2):515-523. PubMed ID: 30348638
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
    Taylor MH; Lee CH; Makker V; Rasco D; Dutcus CE; Wu J; Stepan DE; Shumaker RC; Motzer RJ
    J Clin Oncol; 2020 Apr; 38(11):1154-1163. PubMed ID: 31961766
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
    LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
    BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.
    Kelly K; Infante JR; Taylor MH; Patel MR; Wong DJ; Iannotti N; Mehnert JM; Loos AH; Koch H; Speit I; Gulley JL
    Cancer; 2018 May; 124(9):2010-2017. PubMed ID: 29469949
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors.
    Okamoto W; Yoshino T; Takahashi T; Okamoto I; Ueda S; Tsuya A; Boku N; Nishio K; Fukuoka M; Yamamoto N; Nakagawa K
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1063-71. PubMed ID: 24046058
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
    Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
    Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
    Vonderheide RH; Flaherty KT; Khalil M; Stumacher MS; Bajor DL; Hutnick NA; Sullivan P; Mahany JJ; Gallagher M; Kramer A; Green SJ; O'Dwyer PJ; Running KL; Huhn RD; Antonia SJ
    J Clin Oncol; 2007 Mar; 25(7):876-83. PubMed ID: 17327609
    [TBL] [Abstract][Full Text] [Related]  

  • 54. First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies.
    Irenaeus SMM; Nielsen D; Ellmark P; Yachnin J; Deronic A; Nilsson A; Norlén P; Veitonmäki N; Wennersten CS; Ullenhag GJ
    Int J Cancer; 2019 Sep; 145(5):1189-1199. PubMed ID: 30664811
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors.
    Wei XL; Ren C; Wang FH; Zhang Y; Zhao HY; Zou BY; Wang ZQ; Qiu MZ; Zhang DS; Luo HY; Wang F; Yao S; Xu RH
    Cancer Commun (Lond); 2020 Aug; 40(8):345-354. PubMed ID: 32589350
    [TBL] [Abstract][Full Text] [Related]  

  • 56. First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.
    Meulendijks D; Jacob W; Martinez-Garcia M; Taus A; Lolkema MP; Voest EE; Langenberg MH; Fleitas Kanonnikoff T; Cervantes A; De Jonge MJ; Sleijfer S; Soerensen MM; Thomas M; Ceppi M; Meneses-Lorente G; James I; Adessi C; Michielin F; Abiraj K; Bossenmaier B; Schellens JH; Weisser M; Lassen UN
    Clin Cancer Res; 2016 Feb; 22(4):877-85. PubMed ID: 26463709
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.
    Meulendijks D; Jacob W; Voest EE; Mau-Sorensen M; Martinez-Garcia M; Taus A; Fleitas T; Cervantes A; Lolkema MP; Langenberg MHG; De Jonge MJ; Sleijfer S; Han JY; Calles A; Felip E; Kim SW; Schellens JHM; Wilson S; Thomas M; Ceppi M; Meneses-Lorente G; James I; Vega-Harring S; Dua R; Nguyen M; Steiner L; Adessi C; Michielin F; Bossenmaier B; Weisser M; Lassen UN
    Clin Cancer Res; 2017 Sep; 23(18):5406-5415. PubMed ID: 28600476
    [No Abstract]   [Full Text] [Related]  

  • 58. Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors.
    Hyman DM; Rizvi N; Natale R; Armstrong DK; Birrer M; Recht L; Dotan E; Makker V; Kaley T; Kuruvilla D; Gribbin M; McDevitt J; Lai DW; Dar M
    Clin Cancer Res; 2018 Jun; 24(12):2749-2757. PubMed ID: 29559563
    [No Abstract]   [Full Text] [Related]  

  • 59. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.
    Ribas A; Medina T; Kummar S; Amin A; Kalbasi A; Drabick JJ; Barve M; Daniels GA; Wong DJ; Schmidt EV; Candia AF; Coffman RL; Leung ACF; Janssen RS
    Cancer Discov; 2018 Oct; 8(10):1250-1257. PubMed ID: 30154193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.